Immunotherapy of malignant brain tumors

Immunotherapy against malignant brain tumors – of mice and men

Immunotherapy for Brain Tumors.

Glioblastoma (GBM) is the most lethal form of brain tumor and remains a large, unmet medical need. This review focuses on recent advances in the neurosciences that converge with the broader field of immuno-oncology. Recent findings in neuroanatomy provide a basis for new approaches of cellular therapies for tumors that involve the CNS. The ultimate success of immunotherapy in the CNS will requi...

Immunotherapy for Pediatric Brain Tumors

Malignant brain tumors are the most common cause of solid cancer death in children. New targeted therapies are vital to improve treatment outcomes, but must be developed to enable trafficking across the blood brain barrier (BBB). Since activated T cells cross the BBB, cancer immunotherapy can be harnessed to unlock the cytotoxic potential of the immune system. However, standard of care treatmen...

Cellular immunity and immunotherapy of brain tumors.

Factors influencing the host immune response to central nervous system (CNS) tumors are not yet well understood. This review will outline what is known about anti-tumor immune responses against CNS tumors and describe how advances in our knowledge of basic immunology may be applied to brain tumor immunotherapy. We will first focus on cellular immune system interactions involved in peripheral an...

PATTERN OF MALIGNANT TUMORS IN KERMAN PROVINCE

From March 1980 to March 1989 a total number of 2254 (7.6%) new malignant cases from Kerman province were diagnosed by examination of surgical specimens, blood films and bone marrow smears. The crude relative frequency of cancers was studied and compared with other areas of Iran. Gastric (11.36%) and urinary bladder (7.01 %) carcinomas were significantly more common in Kerman province than...